Vismodegibum
Vismodegibum Uses, Dosage, Side Effects, Food Interaction and all others data.
Vismodegibum inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. FDA approved on Jan 30, 2012.
Vismodegibum selectively binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.
| Trade Name | Vismodegibum |
| Availability | Prescription only |
| Generic | Vismodegib |
| Vismodegib Other Names | Vismodegib, Vismodégib, Vismodegibum |
| Related Drugs | fluorouracil topical, imiquimod topical, Efudex, Aldara, Libtayo, Erivedge |
| Type | |
| Formula | C19H14Cl2N2O3S |
| Weight | Average: 421.297 Monoisotopic: 420.010218428 |
| Protein binding | Vismodegib is highly protein bound with plasma protein binding at about 99%. Vismodegib binds to the plasma proteins, albumin and alpha-1-acid glycoprotein (saturable bnding). |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Vismodegibum is a hedgehog pathway inhibitor used to treat patients with locally advanced or metastatic basal cell carcinoma.
Vismodegibum is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
Vismodegibum is also used to associated treatment for these conditions: Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
How Vismodegibum works
Mutations of the Hedgehog pathway may results in uncontrolled proliferation of skin basal cells. Vismodegibum binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway.
Toxicity
Increased risk of embryo-fetal death and significant birth defects. Common adverse event include muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia.
Food Interaction
- Take with or without food. Food does not affect absorption.
Vismodegibum Drug Interaction
Moderate: diltiazemUnknown: charcoal, sulfamethoxazole / trimethoprim, ubiquinone, copper gluconate, glucose, ethanol, glycerin, heparin, arginine, levocarnitine, cysteine, lithium, valproic acid, thiamine, cyanocobalamin, pyridoxine, cholecalciferol, phytonadione, menaquinone
Vismodegibum Disease Interaction
Volume of Distribution
Vismodegibum has a volume of distribution of 16.4 to 26.6 L.
Elimination Route
The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food.
Half Life
The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.
Elimination Route
Vismodegibum is mostly excreted unchanged, and the main route of elimination is by the feces (82%) and the urine accounts for 4.4%.
Innovators Monograph
You find simplified version here Vismodegibum
